CureVac N.V. (FRA:5CV)
4.516
-0.100 (-2.17%)
Oct 23, 2025, 11:10 AM CET
CureVac Revenue
CureVac had revenue of 1.25M EUR in the quarter ending June 30, 2025, a decrease of -91.38%. This brings the company's revenue in the last twelve months to 510.51M, up 675.15% year-over-year. In the year 2024, CureVac had annual revenue of 535.18M with 895.54% growth.
Revenue (ttm)
510.51M
Revenue Growth
+675.15%
P/S Ratio
2.04
Revenue / Employee
564.72K
Employees
983
Market Cap
1.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 535.18M | 481.42M | 895.54% |
| Dec 31, 2023 | 53.76M | -13.66M | -20.26% |
| Dec 31, 2022 | 67.42M | -35.57M | -34.54% |
| Dec 31, 2021 | 102.99M | 54.12M | 110.74% |
| Dec 31, 2020 | 48.87M | 31.46M | 180.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 46.17B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.28B |
| Merck KGaA | 21.22B |
| Fresenius Medical Care AG | 19.52B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.68B |
| Fielmann Group AG | 2.40B |
CureVac News
- 22 days ago - CureVac: The Hidden Value Of The mRNA Wallet - Seeking Alpha
- 2 months ago - CureVac BV reports Q2 results - Seeking Alpha
- 2 months ago - CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - Wallstreet:Online
- 2 months ago - CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - Accesswire
- 2 months ago - CureVac's 2025 Mid-Year Financial Surge & Key Business Insights - Wallstreet:Online
- 2 months ago - EQS-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - Wallstreet:Online
- 2 months ago - GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled - Seeking Alpha
- 2 months ago - GSK to be paid up to £370 million after patent row settles in US - Evening Standard